Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab and HDMP Followed by Ofatumumab and Alemtuzumab in 17p Deletion CLL
NCT01465334Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2011
- Primary completion
- Nov 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Dana-Farber Cancer Institute. Started Dec 2011; status: terminated.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01465334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01465334.